Developer docs
API playgroundTry for free, no card

Search company profiles

Sofinnova Partners

Full company profile

uuid00005yj

Namestring
Sofinnova Partners
Legal namestring
Sofinnova Partners SAS
Company typeenum
Private
Founded yearint
1972
Descriptiontext

Sofinnova Partners is a privately held European venture capital firm founded in 1972 and headquartered in Paris that invests exclusively across the life-sciences value chain, from seed to later-stage. The firm operates seven dedicated investment strategies — Capital (flagship early-stage biotech/medtech), MD Start (in-house medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare genetic diseases), Digital Medicine (techbio/AI), and Biovelocita (biotech accelerator) — collectively managing over €4 billion in assets and having backed more than 500 companies. Offices in Paris, London, and Milan support investment activity across Europe and the United States.

Sofinnova positions itself as a "company creator" rather than a pure financier, frequently incubating and spinning out companies before founders appear (e.g., MD Start, Biovelocita, Noema Pharma, Bionyra Pharma). At the center of operations is Sofia, a proprietary AI platform trained on 50+ years of internal investment data and deployed on AWS infrastructure; Sofia supports scientific and clinical analysis, market mapping, pitch deck analysis, competitive landscape reports, partnership/licensing insights, and a KOL/executive ranking tool, with a founder-facing version launched through a June 2026 AWS collaboration. The firm is AMF-registered since 1997 and AIFM-authorized since 2014, managing professional FPCI, SLP, and RAIF vehicles, and is GDPR- and SFDR-compliant.

Revenue is generated through three streams: recurring management fees on seven AIFM-authorized fund vehicles; carried interest from successful exits including Actelion→Johnson & Johnson, CoreValve→Medtronic, Shockwave Medical→Johnson & Johnson, Mablink→Eli Lilly, Corvidia→Novo Nordisk, and GlycoVaxyn→GlaxoSmithKline; and long-duration strategic capital from Apollo, which took a minority equity stake in May 2022 alongside an up-to-€1 billion commitment to Sofinnova's investment funds. The firm has raised successive flagship vintages from Capital VI (€260M, 2008) through Capital XI (€650M, 2025), and remains independent and Paris-based.

Short descriptiontext

Sofinnova Partners is a Paris-headquartered European life-sciences venture capital firm founded in 1972, managing €4B+ across seven specialized strategies from seed to later-stage biotech, medtech, and sustainability, having backed 500+ companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, life sciences investing, biopharma early-stage, medtech accelerators, fund management
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Venture Capital — Life Sciences
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fund Management Fees
TypeSubscription Recurring
Description

As an AMF-registered portfolio management company (AIFM authorized since July 2014), Sofinnova earns recurring management fees on its seven investment strategies and their AUM (€4 billion+), which include flagship Capital funds, MD Start, Crossover, Industrial Biotech, Telethon, Digital Medicine, and Biovelocita vehicles.

sofinnovapartners.com
2Carried Interest (Performance Fees) on Funds
TypeLicensing Royalties
Description

Carried interest earned from successful exits and realizations across 500+ portfolio companies including Actelion (J&J), ProQR, CoreValve (Medtronic), Shockwave Medical (J&J), Recor Medical (Otsuka), Mablink (Eli Lilly), Corvidia (Novo Nordisk), GlycoVaxyn (GSK), and Omthera (AstraZeneca).

sofinnovapartners.com
3Strategic Capital from Apollo Partnership
TypeSubscription Recurring
Description

Up to €1 billion commitment from Apollo to Sofinnova's investment funds, with Apollo taking a minority equity stake — providing long-duration capital to accelerate fund growth.

sofinnovapartners.com
Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Pricing details2 tiers
1Professional fund vehicles (FPCI, SLP, RAIF) with management fees and carried interest — only available to qualified investors
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed; accessible only to professional/qualified investors via private placement. No public retail offering.

sofinnovapartners.com
2Equity financing to portfolio companies via seed, Series A, Series B+, and crossover rounds
ModelOtherBilling cadenceMulti-year contract
Notes

Deal-specific equity investments; capital amounts vary by round, e.g., €650M Capital XI fund deploys typically Series A and seed investments; Crossover Strategy invests in clinical-stage biotech/medtech.

sofinnovapartners.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Sofia
Description

Sofinnova's proprietary AI platform, developed to support investing and company building in life sciences, with tools for scientific and clinical analysis, market mapping, and pitch deck analysis. Extended in 2026 through an AWS collaboration to include a founder-facing version.

sofinnovapartners.com
+1 more record
Core offering1 text field

Sofinnova Partners is a venture capital firm that provides equity financing to life-sciences startups from seed through later-stage across seven dedicated investment strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare-disease science), Digital Medicine (techbio/healthtech), and Biovelocita (biotech accelerator). The firm also operates Sofia, a proprietary AI platform built on AWS that supports deal sourcing, scientific and clinical analysis, market mapping, expert ranking, and competitive landscape analysis, with a founder-facing version extended to portfolio startups.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sofinnova Partners operates a multi-fund platform of investment strategies with dedicated specialist teams, rather than a single unified software product. At the center of the firm's operations is Sofia, the proprietary AI platform that supports investing and company building across all strategies by analyzing scientific, clinical, and market data, ranking experts and entrepreneurs, and providing competitive landscape, asset benchmarking, and partnership/licensing insights to founders. The platform is built on more than 50 years of internal Sofinnova data and is being extended through a collaboration with AWS into a founder-facing version for portfolio companies. Around Sofia, the firm offers seven dedicated investment strategies: Sofinnova Capital (flagship early-stage biopharma/medtech), Sofinnova MD Start (medtech accelerator), Sofinnova Crossover (late-stage clinical-stage biotech/medtech), Sofinnova Industrial Biotech (sustainability and industrial biotech), Sofinnova Telethon (Italian rare genetic disease investments), Sofinnova Digital Medicine (techbio and healthtech at the intersection of biology, data, and computation), and Sofinnova Biovelocita (biotech accelerator with European research organizations). Together, Sofia and the seven strategies form an integrated life-sciences investment platform that supports founders from seed to later-stage commercialization across healthcare and sustainability.

Product and service8 records
1Sofinnova Capital Strategy
CategoryInvestment strategy / Flagship early-stage fund
Description

Flagship investment strategy providing equity financing as founding or lead investor in early-stage biopharma and medtech startups developing groundbreaking therapeutic technologies across Europe and the United States. Most recent vintage, Capital XI, closed at €650 million in November 2025 with plans to back 50-60 companies.

2Sofinnova MD Start Strategy
CategoryInvestment strategy / Medtech accelerator
Description

In-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building, turning identified clinical needs into ground-breaking medical devices. Combines direct management, financial support, and access to Sofinnova's infrastructure and network.

3Sofinnova Crossover Strategy
CategoryInvestment strategy / Late-stage crossover fund
Description

Late-stage investment strategy that invests in clinical-stage biotech and medtech companies (both public and private) whose innovations have initial proof of concept, supporting portfolio companies as they achieve clinical milestones and scale toward commercial readiness.

4Sofinnova Industrial Biotech Strategy
CategoryInvestment strategy / Industrial biotech fund
Description

Environmental impact strategy backing early-stage sustainable companies applying biotechnology to the agriculture, food, chemicals, and materials sectors.

5Sofinnova Telethon Strategy
CategoryInvestment strategy / Rare-disease fund
Description

Strategy making early-stage investments in leading Italian science for the benefit of patients with rare genetic diseases, in partnership with the Telethon Foundation. Supported by InnovFin Equity under EU Horizon 2020 and EFSI.

6Sofinnova Digital Medicine Strategy
CategoryInvestment strategy / Digital medicine and techbio fund
Description

Strategy backing early-stage startups innovating at the intersection of biology, data, and computation, working with founders to build companies leveraging AI, machine learning, and data analytics to transform healthcare.

7Sofinnova Biovelocita Strategy
CategoryInvestment strategy / Biotech accelerator
Description

In-house biotech accelerator partnering with Europe's leading research organizations to create and accelerate European biotech start-ups, providing a hands-on, structured framework for company creation built on direct management, financial support, and Sofinnova's infrastructure and network.

8Sofia AI Platform
CategoryProprietary AI platform
Description

Sofinnova's proprietary AI platform that supports investing and company building in life sciences, bringing together tools for scientific and clinical analysis, market mapping, and pitch deck analysis into a single system, powered by more than 50 years of internal data. Being extended to a founder-facing version built on AWS to give portfolio startups access to AI-driven competitive landscape, asset benchmarking, and partnership/licensing tools.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Abingworth is a transatlantic life sciences investment firm with venture and crossover strategies, comparable to Sofinnova's combination of Capital and Crossover. Joe Anderson, now at Sofinnova, previously co-founded Arix and was a partner at Abingworth.

TypeDirect peer
Description

Omega Funds is a Boston-based healthcare and life sciences investment firm active across private and public biotech, comparable to Sofinnova's Crossover strategy. It is an ELSC co-founder.

TypeDirect peer
Description

HealthCap is a Nordic-European life sciences VC firm investing from seed through late-stage biotech and medtech. It is an ELSC co-founder and a directly comparable peer across stages and therapeutic areas.

TypeDirect peer
Description

Forbion is a leading European life sciences VC firm managing multiple funds across biotech and medtech. It is the most direct European peer to Sofinnova's Capital, Crossover, and Biovelocita strategies, and a fellow ELSC co-founder.

TypeOthers
Description

Apollo is a strategic LP and minority equity holder in Sofinnova, and a broader healthcare investor. It is an ecosystem participant rather than a direct competitor, but materially shapes Sofinnova's capital base and growth trajectory.

6EQT Life Sciences (formerly LSP)
TypeDirect peer
Description

EQT Life Sciences is a European healthcare VC platform investing across early and growth stages in biotech and medtech. It is a direct peer to Sofinnova's Capital and Crossover strategies and an existing co-investor (e.g., Neurent Medical).

TypeDirect peer
Description

Atlas Venture is a US/European biotech-focused early-stage VC firm building companies from inception, directly comparable to Sofinnova's Capital and MD Start company-creation model.

TypeDirect peer
Description

Novo Holdings operates early-stage (Novo Seeds) and later-stage (Novo Ventures) life sciences funds, directly competing for European biotech deals. It is also an ELSC co-founder and a co-investor alongside Sofinnova in deals like Hemab.

TypeDirect peer
Description

M Ventures is the strategic corporate venture arm of Merck KGaA, investing in life sciences including biotech, medtech, and digital health across stages. It is comparable to Sofinnova's multi-strategy approach, particularly in Industrial Biotech and Digital Medicine.

TypeDirect peer
Description

Ysios Capital is a Spain-based life sciences VC firm investing in early- and late-stage European biotech. It is closely comparable in strategy and stage focus to Sofinnova Capital and is an established co-investor in European biotech rounds.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers29 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment389 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sofinnova Partners

Venture Capital — Life Sciencessofinnovapartners.com

Sofinnova Partners is a Paris-headquartered European life-sciences venture capital firm founded in 1972, managing €4B+ across seven specialized strategies from seed to later-stage biotech, medtech, and sustainability, having backed 500+ companies.

What Sofinnova Partners does

Sofinnova Partners is a privately held European venture capital firm founded in 1972 and headquartered in Paris that invests exclusively across the life-sciences value chain, from seed to later-stage. The firm operates seven dedicated investment strategies — Capital (flagship early-stage biotech/medtech), MD Start (in-house medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare genetic diseases), Digital Medicine (techbio/AI), and Biovelocita (biotech accelerator) — collectively managing over €4 billion in assets and having backed more than 500 companies. Offices in Paris, London, and Milan support investment activity across Europe and the United States.

Sofinnova positions itself as a "company creator" rather than a pure financier, frequently incubating and spinning out companies before founders appear (e.g., MD Start, Biovelocita, Noema Pharma, Bionyra Pharma). At the center of operations is Sofia, a proprietary AI platform trained on 50+ years of internal investment data and deployed on AWS infrastructure; Sofia supports scientific and clinical analysis, market mapping, pitch deck analysis, competitive landscape reports, partnership/licensing insights, and a KOL/executive ranking tool, with a founder-facing version launched through a June 2026 AWS collaboration. The firm is AMF-registered since 1997 and AIFM-authorized since 2014, managing professional FPCI, SLP, and RAIF vehicles, and is GDPR- and SFDR-compliant.

Revenue is generated through three streams: recurring management fees on seven AIFM-authorized fund vehicles; carried interest from successful exits including Actelion→Johnson & Johnson, CoreValve→Medtronic, Shockwave Medical→Johnson & Johnson, Mablink→Eli Lilly, Corvidia→Novo Nordisk, and GlycoVaxyn→GlaxoSmithKline; and long-duration strategic capital from Apollo, which took a minority equity stake in May 2022 alongside an up-to-€1 billion commitment to Sofinnova's investment funds. The firm has raised successive flagship vintages from Capital VI (€260M, 2008) through Capital XI (€650M, 2025), and remains independent and Paris-based.

Sofinnova Partners firmographics

Firmographics
Name
Sofinnova Partners
Legal name
Sofinnova Partners SAS
Website
https://sofinnovapartners.com
Company type
Private
Founded year
1972
Operating status
Operating
Headcount range
51–100 employees
Short description
Sofinnova Partners is a Paris-headquartered European life-sciences venture capital firm founded in 1972, managing €4B+ across seven specialized strategies from seed to later-stage biotech, medtech, and sustainability, having backed 500+ companies.
Ownership category
akta.pro rank

Sofinnova Partners industry classification

Industry
Product category
Venture Capital — Life Sciences
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital funding
  • Life sciences investing
  • Biopharma early-stage
  • Medtech accelerators
  • Fund management

Where Sofinnova Partners is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Sofinnova Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Fund Management Fees: As an AMF-registered portfolio management company (AIFM authorized since July 2014), Sofinnova earns recurring management fees on its seven investment strategies and their AUM (€4 billion+), which include flagship Capital funds, MD Start, Crossover, Industrial Biotech, Telethon, Digital Medicine, and Biovelocita vehicles.
  2. Carried Interest (Performance Fees) on Funds: Carried interest earned from successful exits and realizations across 500+ portfolio companies including Actelion (J&J), ProQR, CoreValve (Medtronic), Shockwave Medical (J&J), Recor Medical (Otsuka), Mablink (Eli Lilly), Corvidia (Novo Nordisk), GlycoVaxyn (GSK), and Omthera (AstraZeneca).
  3. Strategic Capital from Apollo Partnership: Up to €1 billion commitment from Apollo to Sofinnova's investment funds, with Apollo taking a minority equity stake — providing long-duration capital to accelerate fund growth.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProfessional fund vehicles (FPCI, SLP, RAIF) with management fees and carried interest — only available to qualified investors
OtherMulti-year contractEquity financing to portfolio companies via seed, Series A, Series B+, and crossover rounds

Go-to-market motion4 records

Sofinnova Partners product offering

Product offering

Core offering

Sofinnova Partners is a venture capital firm that provides equity financing to life-sciences startups from seed through later-stage across seven dedicated investment strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare-disease science), Digital Medicine (techbio/healthtech), and Biovelocita (biotech accelerator). The firm also operates Sofia, a proprietary AI platform built on AWS that supports deal sourcing, scientific and clinical analysis, market mapping, expert ranking, and competitive landscape analysis, with a founder-facing version extended to portfolio startups.

Product overview

Sofinnova Partners operates a multi-fund platform of investment strategies with dedicated specialist teams, rather than a single unified software product. At the center of the firm's operations is Sofia, the proprietary AI platform that supports investing and company building across all strategies by analyzing scientific, clinical, and market data, ranking experts and entrepreneurs, and providing competitive landscape, asset benchmarking, and partnership/licensing insights to founders. The platform is built on more than 50 years of internal Sofinnova data and is being extended through a collaboration with AWS into a founder-facing version for portfolio companies. Around Sofia, the firm offers seven dedicated investment strategies: Sofinnova Capital (flagship early-stage biopharma/medtech), Sofinnova MD Start (medtech accelerator), Sofinnova Crossover (late-stage clinical-stage biotech/medtech), Sofinnova Industrial Biotech (sustainability and industrial biotech), Sofinnova Telethon (Italian rare genetic disease investments), Sofinnova Digital Medicine (techbio and healthtech at the intersection of biology, data, and computation), and Sofinnova Biovelocita (biotech accelerator with European research organizations). Together, Sofia and the seven strategies form an integrated life-sciences investment platform that supports founders from seed to later-stage commercialization across healthcare and sustainability.

Differentiator

Problem solved

Functional benefit

Brands

  • Sofia: Sofinnova's proprietary AI platform, developed to support investing and company building in life sciences, with tools for scientific and clinical analysis, market mapping, and pitch deck analysis. Extended in 2026 through an AWS collaboration to include a founder-facing version.
  • BiovelocITA

Products and services

  • Sofinnova Capital Strategy Flagship investment strategy providing equity financing as founding or lead investor in early-stage biopharma and medtech startups developing groundbreaking therapeutic technologies across Europe and the United States. Most recent vintage, Capital XI, closed at €650 million in November 2025 with plans to back 50-60 companies.
  • Sofinnova MD Start Strategy In-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building, turning identified clinical needs into ground-breaking medical devices. Combines direct management, financial support, and access to Sofinnova's infrastructure and network.
  • Sofinnova Crossover Strategy Late-stage investment strategy that invests in clinical-stage biotech and medtech companies (both public and private) whose innovations have initial proof of concept, supporting portfolio companies as they achieve clinical milestones and scale toward commercial readiness.
  • Sofinnova Industrial Biotech Strategy Environmental impact strategy backing early-stage sustainable companies applying biotechnology to the agriculture, food, chemicals, and materials sectors.
  • Sofinnova Telethon Strategy Strategy making early-stage investments in leading Italian science for the benefit of patients with rare genetic diseases, in partnership with the Telethon Foundation. Supported by InnovFin Equity under EU Horizon 2020 and EFSI.
  • Sofinnova Digital Medicine Strategy Strategy backing early-stage startups innovating at the intersection of biology, data, and computation, working with founders to build companies leveraging AI, machine learning, and data analytics to transform healthcare.
  • Sofinnova Biovelocita Strategy In-house biotech accelerator partnering with Europe's leading research organizations to create and accelerate European biotech start-ups, providing a hands-on, structured framework for company creation built on direct management, financial support, and Sofinnova's infrastructure and network.
  • Sofia AI Platform Sofinnova's proprietary AI platform that supports investing and company building in life sciences, bringing together tools for scientific and clinical analysis, market mapping, and pitch deck analysis into a single system, powered by more than 50 years of internal data. Being extended to a founder-facing version built on AWS to give portfolio startups access to AI-driven competitive landscape, asset benchmarking, and partnership/licensing tools.

Companies that use Sofinnova Partners

Customer profile

Named customers29 records

Ideal customer profiles3 records

Sofinnova Partners technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Sofinnova Partners partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Sofinnova Partners competitors and assessment

Company assessment

Direct peers

  • Abingworth: Abingworth is a transatlantic life sciences investment firm with venture and crossover strategies, comparable to Sofinnova's combination of Capital and Crossover. Joe Anderson, now at Sofinnova, previously co-founded Arix and was a partner at Abingworth.
  • Omega Funds: Omega Funds is a Boston-based healthcare and life sciences investment firm active across private and public biotech, comparable to Sofinnova's Crossover strategy. It is an ELSC co-founder.
  • HealthCap: HealthCap is a Nordic-European life sciences VC firm investing from seed through late-stage biotech and medtech. It is an ELSC co-founder and a directly comparable peer across stages and therapeutic areas.
  • Forbion: Forbion is a leading European life sciences VC firm managing multiple funds across biotech and medtech. It is the most direct European peer to Sofinnova's Capital, Crossover, and Biovelocita strategies, and a fellow ELSC co-founder.
  • EQT Life Sciences (formerly LSP): EQT Life Sciences is a European healthcare VC platform investing across early and growth stages in biotech and medtech. It is a direct peer to Sofinnova's Capital and Crossover strategies and an existing co-investor (e.g., Neurent Medical).
  • Atlas Venture: Atlas Venture is a US/European biotech-focused early-stage VC firm building companies from inception, directly comparable to Sofinnova's Capital and MD Start company-creation model.
  • Novo Holdings (Novo Seeds / Novo Ventures): Novo Holdings operates early-stage (Novo Seeds) and later-stage (Novo Ventures) life sciences funds, directly competing for European biotech deals. It is also an ELSC co-founder and a co-investor alongside Sofinnova in deals like Hemab.
  • M Ventures: M Ventures is the strategic corporate venture arm of Merck KGaA, investing in life sciences including biotech, medtech, and digital health across stages. It is comparable to Sofinnova's multi-strategy approach, particularly in Industrial Biotech and Digital Medicine.
  • Ysios Capital: Ysios Capital is a Spain-based life sciences VC firm investing in early- and late-stage European biotech. It is closely comparable in strategy and stage focus to Sofinnova Capital and is an established co-investor in European biotech rounds.

Others

  • Apollo Global Management (Healthcare): Apollo is a strategic LP and minority equity holder in Sofinnova, and a broader healthcare investor. It is an ecosystem participant rather than a direct competitor, but materially shapes Sofinnova's capital base and growth trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Sofinnova Partners social profiles

Digital presence

Sofinnova Partners compliance and trust

Trust signal

Compliance4 records

Sofinnova Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sofinnova Partners leadership team

Management profile

Number of profiles

Profiles9 records

Sofinnova Partners subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Sofinnova Partners funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sofinnova Partners M&A and investment

M&A and investment

M&A

Investments389 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sofinnova Partners

What does Sofinnova Partners do?

Sofinnova Partners is a venture capital firm that provides equity financing to life-sciences startups from seed through later-stage across seven dedicated investment strategies: Capital (flagship early-stage biopharma and medtech), MD Start (medtech accelerator), Crossover (late-stage clinical biotech/medtech), Industrial Biotech (sustainability), Telethon (Italian rare-disease science), Digital Medicine (techbio/healthtech), and Biovelocita (biotech accelerator). The firm also operates Sofia, a proprietary AI platform built on AWS that supports deal sourcing, scientific and clinical analysis, market mapping, expert ranking, and competitive landscape analysis, with a founder-facing version extended to portfolio startups.

Is Sofinnova Partners a public or private company?

Sofinnova Partners is a private company. It is classified as private equity controlled and is currently operating.

When was Sofinnova Partners founded?

Sofinnova Partners was founded in 1972. It employs 51 to 100 people.

Where is Sofinnova Partners based?

Sofinnova Partners is headquartered in Paris, France, in the Europe region.

How does Sofinnova Partners make money?

Three revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest (Performance Fees) on Funds and strategic Capital from Apollo Partnership.

Who are Sofinnova Partners's main competitors?

Direct peers on record are Abingworth, Omega Funds, HealthCap, Forbion, EQT Life Sciences (formerly LSP), Atlas Venture, Novo Holdings (Novo Seeds / Novo Ventures), M Ventures and Ysios Capital. Apollo Global Management (Healthcare) is listed as an others.

Does Sofinnova Partners have an API?

No public API is recorded for Sofinnova Partners.

What industry is Sofinnova Partners in?

Sofinnova Partners's product category is Venture Capital — Life Sciences. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechWhy 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London eventPanelists at Fierce Biotech's London event debated whether 2027 could be Europe's year for biotech investment, with Sofinnova Partners' Antoine Papiernik predicting it. He cited Europe's capital risk and Nasdaq dominance, while Flagship Pioneering announced a London AI-native company creation outpost.StartbaseSofinnova Partners Closes New Life Sciences Fund with 725 Million EurosSofinnova Partners closed its Sofinnova Crossover II life sciences fund at 725 million euros, exceeding its target. The fund will invest in about 15 European biotech and medtech companies, with initial investments already made. It aims to support clinical trials and commercialization.Pulse 2.0Sofinnova Partners: $815 Million Crossover II Fund Closes To Back Late-Stage Life Sciences CompaniesSofinnova Partners closed Sofinnova Crossover II at €725 million ($815 million), exceeding its target. The fund will invest in European clinical-stage biotech and medtech companies, supporting about 15 firms. It builds on Crossover I's track record of acquisitions and public listings.Tech Funding NewsSofinnova Partners closes €725M Crossover II fund to scale European life sciences companies — TFNSofinnova Partners closed its second crossover fund at €725 million, exceeding its target, to back about 15 clinical-stage life sciences companies. The fund focuses on European biopharma and medtech, with selective global investments, and has already invested in three companies.Nate소피노바, 7억2500만 유로 바이오 투자펀드 조성…유럽 신약개발 기업 성장 지원 : 네이트 뉴스Sofinnova Partners raised €725 million for its second crossover fund, the largest of its series, to support European biotech firms. The fund will invest in about 15 companies, including Hemab Therapeutics and CellCentric, and includes participation from the European Technology Champions Initiative.Pharmaceutical TechnologySofinnova Partners backs European life sciences sector with €725M raise - Pharmaceutical TechnologySofinnova Partners closed a €725M ($815M) fund, Crossover II, to support life sciences companies through clinical development and commercialization. The fund will primarily finance about 15 European clinical-stage biopharma and medtech firms, with some capital for US and other regions. It follows a successful first raise that backed companies like Abivax and Amolyt Pharma.MarketScreenerSofinnova closes EUR725 million fund to back European biotech expansionSofinnova Partners closed a EUR725 million crossover fund, above its target, to back European biotechs seeking global competition. The fund, Crossover II, will invest in about 15 companies, including Hemab Therapeutics and CellCentric, and aims to build companies for longevity without M&A.Dealroom.coSofinnova closes $815M crossover fund to back late-stage life sciences | Dealroom NewsSofinnova Partners closed its second crossover fund, Sofinnova Crossover II, at €725 million ($815 million), exceeding its target. The Paris-based firm will back about 15 clinical-stage biopharma and medtech companies, primarily in Europe. The fund roughly doubles its first crossover fund, which closed at €445 million in 2021.MaddynessSofinnova Partners lève 725 millions d’euros pour son fonds Crossover IISofinnova Partners closed its Crossover II fund at €725 million, succeeding a €500 million fund that invested in 16 companies. The fund targets 15-16 biopharma and medtech firms, aiming to support late-stage clinical trials and commercialization. It includes ETCI as a subscriber.BioPharma DiveOne of Europe’s leading VCs banks a €725M ‘crossover’ fundSofinnova Partners raised €725M ($815M) for its second crossover fund, targeting companies near commercialization. The fund will invest in about 15 drugmakers and medical device developers, mostly in Europe. The firm's largest fund has already funded companies like CellCentric and Hemab Therapeutics.